Bristol Myers Squibb (CELG-RI) Liabilities and Shareholders Equity (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $87.6 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 7.44% year-over-year to $87.6 billion; the TTM figure through Jun 2026 stood at $361.0 billion (down 3.3% YoY), while the FY2025 annual figure was $90.0 billion, down 2.77% from the prior year.
• Liabilities and Shareholders Equity climbed to $87.6 billion in Q2 2026 per CELG-RI's latest filing, from $86.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $103.0 billion in Q1 2022 and bottomed at $86.5 billion in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $94.5 billion across 5 years, with a median of $94.5 billion in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity dropped 11.45% — and 2024, when it gained 5.04%.
• Bristol Myers Squibb's Liabilities and Shareholders Equity stood at $96.8 billion in 2022, then fell by 1.72% to $95.2 billion in 2023, then fell by 2.69% to $92.6 billion in 2024, then declined by 2.77% to $90.0 billion in 2025, then decreased by 2.67% to $87.6 billion in 2026.
• Business Quant data shows CELG-RI's Liabilities and Shareholders Equity at $87.6 billion in Q2 2026, $86.5 billion in Q1 2026, and $90.0 billion in Q4 2025.